Thursday 6-12-2014 Johnson & Johnson (JNJ) $JNJ op
Post# of 129
Posted On: 06/12/2014 10:42:48 PM
Thursday 6-12-2014 Johnson & Johnson (JNJ) $JNJ opened at 103.18 hitting the high price of 103.21 and a day low of 102.51 with a total volume of 5,935,011. JNJ had a previous close of 103.32 and has been seeing an average volume of 5,457,365.
Overall Average: 88% Buy
Recent stock forum discussions about JNJ http://investorshangout.com/search?q=JNJ&...mp;yt0=Go!
Final Glance: Pharmaceuticals companies
AP - Thu Jun 12, 5:29PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
Final Glance: Medical Devices companies
AP - Thu Jun 12, 5:29PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were down at the close of trading: (full story)
Corporate Action Network and Injured Women Call on Illinois Attorney General to Investigate Johnson & Johnson
Business Wire - Thu Jun 12, 5:25PM CDT
Corporate Action Network and Illinois women who have been seriously injured by pelvic mesh implants asked Illinois Attorney General Lisa Madigan to investigate Johnson & Johnson (JNJ) for its dangerous pelvic mesh implants, citing their personal health problems and costs incurred by Illinois taxpayers. (full story)
Corporate Action Network and Injured Women Call on Mississippi Attorney General to Investigate Johnson & Johnson
Business Wire - Thu Jun 12, 5:21PM CDT
Corporate Action Network and Mississippi women who have been seriously injured by pelvic mesh implants asked Mississippi Attorney General Jim Hood to investigate Johnson & Johnson (JNJ) for its dangerous pelvic mesh implants, citing their personal health problems and costs incurred by Mississippi taxpayers. (full story)
Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson... (full story)
Is FIFA World Cup Driving Host Hotels? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 3:55PM CDT
Host Hotels & Resorts' (HST) Latin American properties are expected to benefit from increased leisure demand at Rio de Janeiro driven by the FIFA World Cup. (full story)
Midday Glance: Pharmaceuticals companies
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)
Midday Glance: Medical Devices companies
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.: (full story)
Avanir Gains - AVP-825 Hits Phase III Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 11:10AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) announced that AVP-825 met the primary efficacy endpoint in phase III study (COMPASS). (full story)
Early Glance: Pharmaceuticals companies
AP - Thu Jun 12, 9:47AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
Early Glance: Medical Devices companies
AP - Thu Jun 12, 9:47AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.: (full story)
2014 Report on the International Smoking Cessation and Nicotine De-addiction Products (Nicotine Gums, Patches, Lozenges, Inhalers, Sprays, Sublingual, Zyban, Chantix, E-cigarettes) Market - Forecast to 2019
PR Newswire Europe - Thu Jun 12, 8:48AM CDT
DUBLIN, June 12, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/wjrggr/smoking_cessation [http://www.researchandmarkets.com/research/wjrggr/smoking_cessation]) has announced the addition of the "Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" [http://www.researchandmarkets.com/research/wjrggr/smoking_cessation] report to their offering. (full story)
Medtronic Is Great but Its Stock Is Too Expensive for Now
at The Street - Thu Jun 12, 5:30AM CDT
Rumor of a merger pushed the price up. Investors should sit on their hands and wait for the stock to come down. (full story)
Relapsed Multiple Myeloma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg9nqn/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Kyowa Hakko Kirin - Sanofi - Eli Lilly and Company - GlaxoSmithKline - Genentech - Piramal Enterprises - Prolexys - Millennium - Novartis - Astellas - Exelixis - Celgene - Threshold - Synta - Acceleron - Altor BioScience - Arno - Stemline - Noxxon - Acetylon - Pharma - Janssen - AbbVie - Oncopeptides - Senhwa Biosciences For more information visit http://www.researchandmarkets.com/research/hg...d_multiple (full story)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell (full story)
Jim Cramer's 'Mad Money' Recap: Forget Washington and Stay the Course
at The Street - Wed Jun 11, 7:20PM CDT
Nothing turns buyers into sellers faster than wrangling in Washington, Cramer says. (full story)
Is AbbVie's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 11, 5:05PM CDT
AbbVie is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs in 2013. Big drug companies, such as AbbVie, Johnson & Johnson , and Amgen , offer... (full story)
Is Medtronic a Buy? What Analyst Day Revealed
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Jun 11, 4:05PM CDT
Medtronic 's June 6 analyst day was by no means light fare, as the company crammed quite a bit of information into more than seven hours. While action-oriented investors are likely disappointed that management's commentary would seem to... (full story)
Aduro BioTech Secures $55 Million Series C Financing
Business Wire - Wed Jun 11, 3:00PM CDT
Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced the closing of a $55 million Series C financing. New investor Johnson & Johnson Development Corporation (JJDC) joined the Morningside group and other new and existing investors in the transaction. (full story)
Stage Set for FIFA World Cup: 2 Sponsors in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 11:36AM CDT
As the stage is set for the FIFA World Cup 2014 kickoff , 32 participating teams along with 22 corporate sponsors are fine-tuning their plans to make this mega event a grand success. (full story)
Overall Average: 88% Buy
Recent stock forum discussions about JNJ http://investorshangout.com/search?q=JNJ&...mp;yt0=Go!
Final Glance: Pharmaceuticals companies
AP - Thu Jun 12, 5:29PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading: (full story)
Final Glance: Medical Devices companies
AP - Thu Jun 12, 5:29PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were down at the close of trading: (full story)
Corporate Action Network and Injured Women Call on Illinois Attorney General to Investigate Johnson & Johnson
Business Wire - Thu Jun 12, 5:25PM CDT
Corporate Action Network and Illinois women who have been seriously injured by pelvic mesh implants asked Illinois Attorney General Lisa Madigan to investigate Johnson & Johnson (JNJ) for its dangerous pelvic mesh implants, citing their personal health problems and costs incurred by Illinois taxpayers. (full story)
Corporate Action Network and Injured Women Call on Mississippi Attorney General to Investigate Johnson & Johnson
Business Wire - Thu Jun 12, 5:21PM CDT
Corporate Action Network and Mississippi women who have been seriously injured by pelvic mesh implants asked Mississippi Attorney General Jim Hood to investigate Johnson & Johnson (JNJ) for its dangerous pelvic mesh implants, citing their personal health problems and costs incurred by Mississippi taxpayers. (full story)
Is Amgen's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Thu Jun 12, 4:30PM CDT
Amgen is one of the globe's biggest drug companies, and investors looking to sprinkle growth-oriented biotechnology companies into dividend portfolios often consider buying its shares. Big drug companies such as Amgen, AbbVie , and Johnson... (full story)
Is FIFA World Cup Driving Host Hotels? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 3:55PM CDT
Host Hotels & Resorts' (HST) Latin American properties are expected to benefit from increased leisure demand at Rio de Janeiro driven by the FIFA World Cup. (full story)
Midday Glance: Pharmaceuticals companies
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.: (full story)
Midday Glance: Medical Devices companies
AP - Thu Jun 12, 12:19PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.: (full story)
Avanir Gains - AVP-825 Hits Phase III Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 11:10AM CDT
Avanir Pharmaceuticals, Inc. (AVNR) announced that AVP-825 met the primary efficacy endpoint in phase III study (COMPASS). (full story)
Early Glance: Pharmaceuticals companies
AP - Thu Jun 12, 9:47AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.: (full story)
Early Glance: Medical Devices companies
AP - Thu Jun 12, 9:47AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.: (full story)
2014 Report on the International Smoking Cessation and Nicotine De-addiction Products (Nicotine Gums, Patches, Lozenges, Inhalers, Sprays, Sublingual, Zyban, Chantix, E-cigarettes) Market - Forecast to 2019
PR Newswire Europe - Thu Jun 12, 8:48AM CDT
DUBLIN, June 12, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/wjrggr/smoking_cessation [http://www.researchandmarkets.com/research/wjrggr/smoking_cessation]) has announced the addition of the "Smoking Cessation and Nicotine De-addiction Products Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" [http://www.researchandmarkets.com/research/wjrggr/smoking_cessation] report to their offering. (full story)
Medtronic Is Great but Its Stock Is Too Expensive for Now
at The Street - Thu Jun 12, 5:30AM CDT
Rumor of a merger pushed the price up. Investors should sit on their hands and wait for the stock to come down. (full story)
Relapsed Multiple Myeloma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 3:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg9nqn/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Kyowa Hakko Kirin - Sanofi - Eli Lilly and Company - GlaxoSmithKline - Genentech - Piramal Enterprises - Prolexys - Millennium - Novartis - Astellas - Exelixis - Celgene - Threshold - Synta - Acceleron - Altor BioScience - Arno - Stemline - Noxxon - Acetylon - Pharma - Janssen - AbbVie - Oncopeptides - Senhwa Biosciences For more information visit http://www.researchandmarkets.com/research/hg...d_multiple (full story)
B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014
M2 - Thu Jun 12, 2:39AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fvkt8j/bcell) has announced the addition of the "B-Cell Non-Hodgkin Lymphoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of B-Cell Non-Hodgkin Lymphoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for B-Cell Non-Hodgkin Lymphoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Mentioned: - Bristol-Myers Squibb Company - Johnson & Johnson - Boehringer Ingelheim - Amgen - Sanofi - Seattle Genetics - Genentech - MedImmune - Merck & Co - Millennium Pharmaceuticals - Biocon Limited - Ono Pharmaceutical - Sandoz - Celgene Corporation - Incyte Corporation - Merck KGaA - Immunomedics - Portola Pharmaceuticals - Pharmacyclics - Senesco Technologies - Simcere Pharmaceutical - Spectrum Pharmaceuticals - Abiogen Pharma. - Provenance Biopharmaceuticals - LFB Biotechnologies - Areta International - Molecular Templates - Aprogen - BioMedics Japan - Pharmapraxis For more information visit http://www.researchandmarkets.com/research/fvkt8j/bcell (full story)
Jim Cramer's 'Mad Money' Recap: Forget Washington and Stay the Course
at The Street - Wed Jun 11, 7:20PM CDT
Nothing turns buyers into sellers faster than wrangling in Washington, Cramer says. (full story)
Is AbbVie's Dividend Safe?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jun 11, 5:05PM CDT
AbbVie is one of the globe's top drugmakers and it's quickly become a staple in dividend investors' portfolios since separating from Abbott Labs in 2013. Big drug companies, such as AbbVie, Johnson & Johnson , and Amgen , offer... (full story)
Is Medtronic a Buy? What Analyst Day Revealed
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Jun 11, 4:05PM CDT
Medtronic 's June 6 analyst day was by no means light fare, as the company crammed quite a bit of information into more than seven hours. While action-oriented investors are likely disappointed that management's commentary would seem to... (full story)
Aduro BioTech Secures $55 Million Series C Financing
Business Wire - Wed Jun 11, 3:00PM CDT
Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced the closing of a $55 million Series C financing. New investor Johnson & Johnson Development Corporation (JJDC) joined the Morningside group and other new and existing investors in the transaction. (full story)
Stage Set for FIFA World Cup: 2 Sponsors in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 11:36AM CDT
As the stage is set for the FIFA World Cup 2014 kickoff , 32 participating teams along with 22 corporate sponsors are fine-tuning their plans to make this mega event a grand success. (full story)
(0)
(0)Johnson & Johnson (JNJ) Stock Research Links
Scroll down for more posts ▼